Results · Jul-Sep 2026 · filed 14 Oct 2026
Bacil Pharma Q2 FY27 results
Sales were ₹0 crore against ₹0 crore in Jul-Sep 2025.
Net profit turned into a loss of ₹0.01 crore, from a profit of ₹0.01 crore in Jul-Sep 2025.
Against Apr-Jun 2026: loss narrows.
Jul-Sep 2026 vs a year ago
| ₹ crore | Jul-Sep 2026 | Jul-Sep 2025 | Change |
|---|---|---|---|
| Sales | 0.0 | 0.0 | n/m |
| Operating profit (EBITDA) | -0.1 | -0.0 | n/m |
| Net profit | -0.0 | 0.0 | swings to a loss |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 14 Oct 2026Un-Audited Financial Result For The Quarter And Half Yearly Ended 30Th September, 2026
- 14 Oct 2026Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th October, 2026
- 12 Oct 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.